TEC-ADHERE

Treatment tested

• Dimethyl fumarate

  Kelch-like ECH-associated protein 1 inhibitor

• PSP

Other measures (11)

Key Inclusion Criteria: * Ability to understand the purpose and risks of the study and giving oral informed consent regarding TEC-ADHERE study and authorization to use protected health information (PHI) in accordance with national and local participant privacy regulations; * Diagnosis of RR-MS; * Initiating oral DMF according to Summary of Product Characteristics (SmPC) at the inclusion visit; * Expanded Disability Status Score (EDSS) under 6. Key Exclusion Criteria: * Participants with progressive form of Multiple Sclerosis (MS); * With memory or psychiatric disorders preventing them to complete questionnaires in the study. Note: Other protocol defined Inclusion/Exclusion criteria may apply.

The primary objective is to compare oral dimethyl fumarate (DMF) persistence at six months in relapsing-remitting multiple sclerosis (RR-MS) participants initiating DMF with and without OroSEP patient support program (PSP), respectively. The secondary objectives are: to compare oral DMF persistence at one month and three months in RR-MS participants initiating DMF with and without OroSEP PSP, respectively; To compare oral DMF adherence at six months in RR-MS participants initiating DMF with and without OroSEP PSP; To compare at three months and six months the reason of oral DMF discontinuation, in the two groups; To describe the percentage of participants with treatment-related adverse events globally and by class of adverse events, in the two groups of participants; To assess the evolution of participants' anxiety globally and to compare it at inclusion and at six months in participants with and without OroSEP PSP, respectively; To describe participants' satisfaction regarding oral DMF initiation and follow-up globally at six months and to compare it in patients with and without OroSEP PSP, respectively; For OroSEP PSP group: To assess participants' satisfaction regarding their participation in OroSEP PSP at six months; To assess neurologists' satisfaction regarding their participation in OroSEP PSP, after the last participant last visit of center.